Gain Therapeutics, Inc.
GANX
$1.65
-$0.04-2.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 14.13% | 9.03% | -28.23% | -20.22% | 16.00% |
| Total Depreciation and Amortization | 40.74% | 16.13% | -4.12% | 4.30% | -3.13% |
| Total Amortization of Deferred Charges | 8.33% | -7.69% | 18.18% | -8.33% | 0.00% |
| Total Other Non-Cash Items | -12.32% | -60.60% | 125.91% | -42.07% | 191.51% |
| Change in Net Operating Assets | -284.67% | 73.26% | -419.58% | 125.57% | 67.75% |
| Cash from Operations | 6.25% | 3.38% | -33.43% | -10.62% | 43.15% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -3.31% | -9.01% | 2.63% | 1.30% |
| Issuance of Common Stock | 122.40% | 199.22% | 2.96% | 3.58% | 180.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | -- | -- | -- | -- |
| Cash from Financing | 135.34% | 185.11% | 2.90% | 3.64% | 185.99% |
| Foreign Exchange rate Adjustments | 1,359.70% | -97.42% | 137.53% | 122.78% | -225.55% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 469.33% | 189.08% | -80.41% | 21.06% | 65.90% |